Neoplasms

Blood and Lymph Conditions

Immune System Diseases

All Conditions

Heart and Blood Diseases

Rare Diseases

Lymphoma

Multiple Myeloma

Neoplasms, Plasma Cell

Lymphoma, Mantle-Cell

Lymphoma, Follicular

Lymphoma, Large B-Cell, Diffuse

Lymphoma, B-Cell

Waldenstrom Macroglobulinemia

Lymphoma, Non-Hodgkin

Neoplasms by Histologic Type

Lymphoproliferative Disorders

Lymphatic Diseases

Immunoproliferative Disorders

Hemostatic Disorders

Blood Coagulation Disorders

Vascular Diseases

Paraproteinemias

Blood Protein Disorders

Hematologic Diseases

Hemorrhagic Disorders

Lymphosarcoma

Mantle Cell Lymphoma

Follicular Lymphoma

B-cell Lymphoma

Diffuse Large B-Cell Lymphoma

Indolent B Cell Lymphoma

All Drugs and Chemicals

Antineoplastic Agents

Antirheumatic Agents

Micronutrients

Vasodilator Agents

Lipid Regulating Agents

Analgesics

Hematinics

Vitamins

Antibodies

Antibodies, Monoclonal

Cyclophosphamide

Fludarabine

Fludarabine phosphate

Rituximab

Niacinamide

Niacin

Nicotinic Acids

Immunoglobulins

Interleukin-2

Elotuzumab

Folic Acid

Vitamin B Complex

Trace Elements

Hypolipidemic Agents

Antimetabolites

Nicotinamide

Nicotinic Acid

Vitamin B3

Folate

Vitamin B9

After a lymphodepleting preparative regimen of cyclophosphamide and fludarabine, patients receive expanded NAM-NK cells followed by a short course of interleukin-2 (IL-2) to facilitate natural killer cell survival and expansion in vivo. Monoclonal antibodies and elotuzumab for Multiple Myeloma patients, will be administered prior to and after the natural killer cell infusion(s) to facilitate tumor targeting and antibody dependent cellular cytotoxicity (ADCC).

After a lymphodepleting preparative regimen of cyclophosphamide and fludarabine, patients receive expanded NAM-NK cells followed by a short course of interleukin-2 (IL-2) to facilitate natural killer cell survival and expansion in vivo. Monoclonal antibodies and rituximab for Non-Hodgkin Lymphoma patients, will be administered prior to and after the natural killer cell infusion(s) to facilitate tumor targeting and antibody dependent cellular cytotoxicity (ADCC).

* Cyclophosphamide 40 mg/kg x 1 day on Day -5
* Fludarabine 25 mg/m\^2 x 3 days (Day -5, Day -4, day-3)

Nicotinamide Expanded Haploidentical or Mismatched Related Donor Natural Killer Cells

Veronika Bachanova, MD, PhD

This is a phase I trial with pilot expansion of HLA-haploidentical or HLA-mismatched related donor nicotinamide expanded-natural killer (NAM-NK) cell based therapy for patients with relapsed or refractory multiple myeloma (MM) or relapsed/refractory CD20-positive non-Hodgkin lymphoma (NHL). The primary endpoint of the study is to determine the maximum tolerated dose (MTD) of NAM-NK cells while maintaining safety.

Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL

A Phase I Trial Testing NAM Expanded Haploidentical or Mismatched Related Donor Natural Killer (NK) Cells Followed by a Short Course of IL-2 for the Treatment of Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory CD20+ Non-Hodgkin Lymphoma

Masonic Cancer Center, University of Minnesota

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL	NCT03019666	Multiple Myelom... Non-Hodgkin Lym... Diffuse Large B... Mantle-Cell Lym... Follicular Lymp... Indolent B Cell... Primary Mediast... Lymphoplasmacyt...	Nicotinamide Ex...	18 Years - 70 Years	Masonic Cancer Center, University of Minnesota
Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL	NCT03019666	Multiple Myelom... Non-Hodgkin Lym... Diffuse Large B... Mantle-Cell Lym... Follicular Lymp... Indolent B Cell... Primary Mediast... Lymphoplasmacyt...	Nicotinamide Ex...	18 Years - 70 Years	Masonic Cancer Center, University of Minnesota

Spots Global Cancer Trial Database for nicotinamide expanded haploidentical or mismatched related donor natural killer cells